Introduction
Wilson disease is one of the typical inborn errors of copper metabolism caused by autosomal recessive heredity. The causal gene, ATP7B, is located at 13q14.3, and the cDNA for ATP7B was isolated in 1993 (Yamaguchi et al. 1993; Bull et al. 1993; Petrukhin et al. 1993; Tanzi et al. 1993) . The putative product protein of this gene has been thought to be a membrane protein with six copper-binding sites that belongs to a P-type ATPase family (Culotta and Gitlin 2001) . Previous reports have suggested that this protein is involved in excretion of copper from hepatic cells and synthesis of active ceruloplasmin (Culotta and Gitlin 2001) . Wilson disease is characterized by dysfunction of this protein, which causes abnormal accumulation of copper in various tissue, such as the liver, basal ganglia, and cornea. Major clinical signs are hepatic dysfunction, extrapyramidal dysfunction, and Kayser-Fleischer rings, as well as other clinical manifestations. Episodes of the disease also vary greatly among patients; they are classified into hepatic, neurological, fulminant, hepatoneurological, and presymptomatic types (Aoki 1984) .
Despite variations in clinical symptoms, it has been thought that sibling patients usually show an identical disease type, and that the age at onset of the disease is almost identical among the siblings (Ferenci 2001) . However, we here report two families with Wilson disease in which siblings showed different disease types and different ages at onset. We carried out mutation analysis of the ATP7B gene for sibling patients. Clinical symptoms, clinical courses, and possible involvement of genetic mutations in these cases are described.
Subjects and methods

Family 1
Three sibling patients (a 52-year-old woman, a 50-year-old man, and a 42-year-old man) were investigated (Fig. 1) .
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Their parents were not consanguineous, and there was a clinically healthy female sibling (the third child) without biochemical abnormality (serum ceruloplasmin level, serum copper level, and urinary copper excretion were normal). The 50-year-old man, the second child, exhibited neurological manifestations such as agraphia and dysarthria at the age of 16 years. The patient was treated with dpenicillamine, but the symptoms progressively worsened and he is currently bedridden. This patient represents the severe neurological type of Wilson disease (Table 1) . The 42-year-old man (fourth child) also showed involuntary movement and agraphia at the age of 28 years. Treatment with d-penicillamine was started but then discontinued because the patient had nephrotic syndrome as an adverse reaction. d-Penicillamine was subsequently replaced by trientine when the patient was 33 years old. He has shown satisfactory improvement and is currently free from difficulty in daily living, except for mild dysdiadochokinesis (Table 1) . The first child, a 52-year-old woman, was diagnosed as having hepatic dysfunction at the age of 38 years when she was pregnant. Close examination established a final diagnosis of hepatic type of Wilson disease. Administration of d-penicillamine was started, but the drug was replaced by trientine because urinary protein was detected. The clinical course after trientine administration was excellent, and she is currently free from any clinical symptoms. She has the mild hepatic type of Wilson disease (Table 1) .
Family 2
Two siblings (a 36-year-old woman and a 34-year-old man) presented with Wilson disease (Fig. 2) . Their parents were not consanguineous. The third child, a 22-year-old man, was clinically healthy and biochemically normal. His serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), ceruloplasmin, and copper levels were within normal limits, and urinary copper excretion was not elevated. The Table 2 ). The patient was initially treated with d-penicillamine, but because of side effects is currently being treated with trientine. The 36-year-old woman, the first child, underwent close examination after her younger brother was diagnosed as having Wilson disease. The results showed hepatic dysfunction (increase in AST and ALT), and further examination by abdominal ultrasonography also detected a mild lesion in the liver. Moreover, a decrease in the serum level of ceruloplasmin and increases in urinary copper excretion and in hepatic copper content were observed, which led to the diagnosis of hepatic-type Wilson disease. This patient demonstrates the mild hepatic type (Table 2) . Treatment with d-penicillamine was started, but adverse reactions such as systematic eruption and proteinuria occurred. d-Penicillamine was therefore replaced by trientine, and the patient is currently showing satisfactory progress. Gene analysis Structural analysis of the causal gene (ATP7B) for the disease was performed for three patients in family 1 and one in family 2, after obtaining informed consent. Genomic DNA was extracted from the peripheral blood, and each exon of the ATP7B gene was amplified by polymerase chain reaction (PCR) (Shimizu et al. 1995 (Shimizu et al. , 1999 . Nine exons (exon 5, 8, 10, 11, 12, 13, 14, 16, and 18) were selected for the first analysis on the basis of previous studies (Shimizu et al. 1995 (Shimizu et al. , 1999 Takeshita 2000; Yamaguchi et al. 1998; Okada et al. 2000) , which had demonstrated a higher frequency of mutations in specific exons of the ATP7B gene of Japanese patients with Wilson disease. Amplified PCR products were directly sequenced using an automated sequencer (ABI373S or 3700; ABI, CA, USA) to identify mutations. The results indicated that family 1 was compound heterozygous for mutations R778L (exon 8) and R919G (exon 12) (Fig. 3) , and family 2 for 2511delA (exon 10) and A874V (exon 11) (Fig. 4) .
Discussion
The age at onset of Wilson disease varies from childhood to the fifties, and clinical expression also shows a wide variety. This disease is classified into five types by clinical course (Aoki 1984) . Presymptomatic Wilson disease is detected and diagnosed during the asymptomatic period. The hepatic type demonstrates hepatic symptoms and/or liver dysfunction without any neurological symptoms. The neurological type demonstrates neurological symptoms only, without liver dysfunction. The hepatoneurological type shows both liver dysfunction and neurological symptoms during the disease course. The fulminant type is the most severe type of Wilson disease, showing sudden onset of fulminant hepatic failure and hemolytic anemia. It has been reported that hepatic disorders are major symptoms during childhood, and cranial neuropathy becomes evident during puberty and adolescence (Shimizu 2001 ). An epidemiological study of the disease has indicated that hepatic dysfunction appears earlier than neuropathy, and that the age at onset of the hepatic type is lower than that of the neurological type (Aoki 1984) . In addition, disease types and the age of onset are known to be almost identical among sibling patients (Ferenci 2001) . Thus, these two families with Wilson disease In family 1, the second and the fourth male children showed the neurological type, whereas the first female child exhibited the hepatic type 10-20 years later than the onset in her younger brothers. The age at onset of the neurological type also showed a marked difference between the two male siblings. It was suggested that the clinical courses in these siblings might be rare in Wilson disease.
Also in family 2, the younger male child (the second child) showed neurological symptoms earlier than the first female child. It should be noted that the age at onset of the male patient was 32 years, much later than that of most neurological-type patients. Hepatic dysfunction was de-
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A A A C C N G T C 120 Fig. 3A-D tected in the first female child, who was also diagnosed as having Wilson disease. This familial case might also be rare, and the symptoms were suggested to be rather mild in this family. Although the exact mechanisms by which the siblings of these two families showed different clinical phenotypes and by which the neurological types occurred earlier than the hepatic types are unknown, several explanations are possible. There has been a report that the prevalence of severe hepatic dysfunction is slightly higher in females in Europe and the United States than in men (Culotta and Gitlin 2001) . In this study, both women showed hepatic forms of the disease, suggesting that a gender difference is associated with the observation. However, it has been demonstrated that the copper content tends to be higher in patients with the neurological type of Wilson disease than in those with the hepatic type (Shimizu et al. 1998 ). There might be individual differences in the severity of copper accumulation in hepatic cells associated with the expression of metallothionein and in the tolerance of hepatic and/or neuronal cells against copper toxicity. The present observation that siblings showed different clinical phenotypes and different ages at onset of Wilson disease in some families is suggestive of the importance of family screening, including older siblings, if a proband is diagnosed as having Wilson disease.
To elucidate the pathology of these cases, we carried out mutation analysis of the ATP7B gene. Both families were found to be compound heterozygotes for the mutation. The R778L mutation detected in family 1 was identical to that found in neurological patients at a significantly higher frequency, as revealed in our previous studies (Takeshita 2000; Shimizu et al. 2000) . The relationship between the R919G mutation occurring on the other allele and phenotypes remains uncertain. Family 2 demonstrated a compound heterozygote of the frameshift mutation and the missense mutation. It has been suggested that frameshift mutation is more frequently detected in the hepatic type (Shimizu et al. 2000) . These results raise the possibility that the dominance of the allele expressing the ATP7B protein differs among patients, which might result in different clinical phenotypes. Functional and anatomical analyses on the expressed ATP7B protein are necessary to elucidate the relationship between genetic mutations and clinical phenotypes of the disease. In addition, the structure of the ATP7B protein, its ability to transport copper, and its localization within hepatic cells should be clarified in future studies. Furthermore, the association of the mutant proteins with various in vivo dysfunctions should be examined to clarify the pathological mechanisms in Wilson disease.
